Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres-Reference-Cited by-同舟云学术

Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres

Published:2020-09 Issue: Volume:24 Page:100618
ISSN:2214-4269
Container-title:Molecular Genetics and Metabolism Reports
language:en
Short-container-title:Molecular Genetics and Metabolism Reports

Author:

Mhanni Aizeddin A.,Auray-Blais Christiane,Boutin Michel,Johnston Alie,LeMoine Kaye,Patterson Jill,Aerts Johannes M.F.G.,West Michael L.,Rockman-Greenberg Cheryl

Funder

Children's Hospital Research Institute of Manitoba

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology

Reference38 articles.

1. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics;Auray-Blais;Anal. Chem.,2012

2. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry;Auray-Blais;Clin. Chim. Acta,2015

3. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation;Auray-Blais;Clin. Chim. Acta,2017

4. High-risk screening for Fabry disease: analysis by tandem mass spectrometry of globotriaosylceramide (Gb3) in urine collected on filter paper;Auray-Blais;Curr. Protoc. Hum. Genet.,2017

5. Urinary Globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease;Auray-Blais;Mol. Genet. Metab.,2008

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabry nephropathy: a treatable cause of chronic kidney disease;Rare Disease and Orphan Drugs Journal;2024-07-11

2. Advances in Immune Tolerance Induction in Enzyme Replacement Therapy;Pediatric Drugs;2024-04-25

3. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients;Internal Medicine;2024

4. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease;Drugs;2021-11